The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
The anti-angiogenic basis of metronomic chemotherapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Isolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Takahashi, T., Kalka, C., Masuda, H., Chen, D., Silver, M., Kearney, M., Magner, M., Isner, J. M., & Asahara, T. (1999) · Nature Medicine · doi:10.1038/7434 · Cited by 2,423
Principles and Practice of Pediatric Oncology
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-8-636_3 · Cited by 2,027
Gerber, H.-P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., & Ferrara, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30336 · Cited by 1,981
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J., & Keshet, E. (1995) · Nature Medicine · doi:10.1038/nm1095-1024 · Cited by 1,604
Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis
Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Lyden, D., Rafii, S., Haimovitz-Friedman, A., Fuks, Z., & Kolesnick, R. (2003) · Science · doi:10.1126/science.1082504 · Cited by 1,593
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.
Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, B. M., Edwards, D. A., Flickinger, A. G., Moore, R. J., & Seibert, K. (2000) · PubMed · Cited by 1,401
Crawford, J., Ozer, H., Stoller, R., Johnson, D., Lyman, G., Tabbara, I., Kris, M., Grous, J., Picozzi, V., Rausch, G., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107183250305 · Cited by 1,390
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Self-citationIntergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease
Crist, W. M., Anderson, J. R., Meza, J. L., Fryer, C., Raney, R. B., Ruymann, F. B., Breneman, J., Qualman, S. J., Wiener, E., Wharam, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.3091 · Cited by 1,087
Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy
Ezekowitz, R. A. B., Mulliken, J. B., & Folkman, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205283262203 · Cited by 1,071
Principles and Practice of Pediatric Oncology
Labotka, R. J. (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.7.894-a · Cited by 1,046
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
Jiménez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., & Bouck, N. (2000) · Nature Medicine · doi:10.1038/71517 · Cited by 1,020
Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Mauceri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., et al. (1999) · PubMed · Cited by 947
Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., & Augustin, H. G. (2000) · PubMed · Cited by 873
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization
Heeschen, C., Aicher, A., Lehmann, R., Fichtlscherer, S., Vasa, M., Urbich, C., Mildner-Rihm, C., Martin, H., Zeiher, A. M., & Dimmeler, S. (2003) · Blood · doi:10.1182/blood-2003-01-0223 · Cited by 845
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Self-citationA Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung
Kato, H., Ichinose, Y., Ohta, M., Hata, E., Tsubota, N., Tada, H., Watanabe, Y., Wada, H., Tsuboi, M., Hamajima, N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032792 · Cited by 818
Newlands, E. S., Stevens, M. F. G., Wedge, S. R., Wheelhouse, R. T., & Brock, C. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90019-0 · Cited by 817
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
Rafii, S., Lyden, D., Benezra, R., Hattori, K., & Heissig, B. (2002) · Nature Reviews Cancer · doi:10.1038/nrc925 · Cited by 679
CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells
Dawson, D. W., Pearce, S. F. A., Zhong, R., Silverstein, R. L., Frazier, W. A., & Bouck, N. P. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.3.707 · Cited by 676
Combined effects of angiostatin and ionizing radiation in antitumour therapy
Mauceri, H. J., Hanna, N. N., Beckett, M. A., Gorski, D. H., Staba, M.-J., Stellato, K. A., Bigelow, K., Heimann, R., Gately, S., Dhanabal, M., et al. (1998) · Nature · doi:10.1038/28412 · Cited by 668
Morgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 652
The microtubule-affecting drug paclitaxel has antiangiogenic activity.
Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., & Taraboletti, G. (1996) · PubMed · Cited by 643
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth
Lawler, J. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00307.x · Cited by 540
Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nolè, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf013 · Cited by 496
Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., & Kerbel, R. S. (2003) · PubMed · Cited by 462
Self-citationBocci, G., Nicolaou, K. C., & Kerbel, R. S. (2002) · PubMed · Cited by 444
Self-citationKerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441
Self-citationA role for survivin in chemoresistance of endothelial cells mediated by VEGF
Tran, J., Master, Z., Yu, J. L., Rak, J., Dumont, D. J., & Kerbel, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072586399 · Cited by 434
Self-citationEffect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426
Self-citationThrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
Bocci, G., Francia, G., Man, S., Lawler, J., & Kerbel, R. S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135406100 · Cited by 414
Self-citationRedefining the Target: Chemotherapeutics as Antiangiogenics
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1195 · Cited by 395
Wachsberger, P. R., Burd, R., & Dicker, A. P. (2003) · PubMed · Cited by 395
Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., & Fidler, I. J. (1999) · PubMed · Cited by 337
Tran, J., Rak, J., Sheehan, C., Saibil, S. D., LaCasse, E., Korneluk, R. G., & Kerbel, R. S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1589 · Cited by 333
Self-citationSweeney, C. J., Miller, K. D., Sissons, S. E., Nozaki, S., Heilman, D. K., Shen, J., & Sledge, G. W. (2001) · PubMed · Cited by 331
Man, S., Bocci, G., Francia, G., Green, S. K., Jothy, S., Hanahan, D., Böhlen, P., Hicklin, D. J., Bergers, G., & Kerbel, R. S. (2002) · PubMed · Cited by 314
Self-citationWitte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., & Böhlen, P. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006094117427 · Cited by 307
Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino, F., Brignole, C., Marimpietri, D., Cilli, M., Gambini, C., Ribatti, D., Longhi, R., Allen, T. M., Corti, A., & Ponzoni, M. (2003) · PubMed · Cited by 296
Guo, N., Krutzsch, H. C., Inman, J. K., & Roberts, D. D. (1997) · PubMed · Cited by 293
Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine
Vacca, A., Iurlaro, M., Ribatti, D., Minischetti, M., Nico, B., Ria, R., Pellegrino, A., & Dammacco, F. (1999) · Blood · doi:10.1182/blood.v94.12.4143 · Cited by 279
Mandriota, S. J., Seghezzi, G., Vassalli, J.-D., Ferrara, N., Wasi, S., Mazzieri, R., Mignatti, P., & Pepper, M. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.17.9709 · Cited by 267
Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease.
Teicher, B. A., Sotomayor, E. A., & Huang, Z. D. (1992) · PubMed · Cited by 260
Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer
Burstein, H. J., Manola, J., Younger, J., Parker, L. M., Bunnell, C. A., Scheib, R., Matulonis, U. A., Garber, J. E., Clarke, K. D., Shulman, L. N., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1212 · Cited by 260
Su, Y. B., Sohn, S., Krown, S. E., Livingston, P. O., Wolchok, J. D., Quinn, C., Williams, L., Foster, T., Sepkowitz, K. A., & Chapman, P. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.060 · Cited by 257
Metronomic scheduling: the future of chemotherapy?
Gasparini, G. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00587-3 · Cited by 251
Antiangiogenic Therapy of a Recurrent Giant Cell Tumor of the Mandible With Interferon Alfa-2a
Kaban, L. B., Mulliken, J. B., Ezekowitz, R. A., Phil, D., Ebb, D., Smith, P. S., & Folkman, J. (1999) · Pediatrics · doi:10.1542/peds.103.6.1145 · Cited by 245
Ruzinova, M. B., Schoer, R. A., Gerald, W., Egan, J. E., Pandolfi, P. P., Rafii, S., Manova, K., Mittal, V., & Benezra, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00240-x · Cited by 244
Klement, G. L., Huang, P. H., Mayer, B., Green, S. K., Man, S., Böhlen, P., Hicklin, D. J., & Kerbel, R. S. (2002) · PubMed · Cited by 243
Self-citationFennelly, D., Aghajanian, C., Shapiro, F., O'Flaherty, C., McKenzie, M., O'Connor, C., Tong, W., Norton, L., & Spriggs, D. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.1.187 · Cited by 242
Wang, J., Lou, P., Lesniewski, R., & Henkin, J. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200301000-00003 · Cited by 212
Hirata, S., Matsubara, T., Saura, R., Hirohata, K., & Tateishi, H. (1989) · Arthritis & Rheumatism · doi:10.1002/anr.1780320903 · Cited by 201
Gupta, K., Gupta, P. K., Wild, R., Ramakrishnan, S., & Hebbel, R. P. (1999) · Angiogenesis · doi:10.1023/a:1009018702832 · Cited by 185
Hamano, Y., Sugimoto, H., Soubasakos, M. A., Kieran, M., Olsen, B. R., Lawler, J., Sudhakar, A., & Kalluri, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3126 · Cited by 185
Mesri, M., Morales-Ruiz, M., Ackermann, E. J., Bennett, C. F., Pober, J. S., Sessa, W. C., & Altieri, D. C. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64131-4 · Cited by 183
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo.
Bello, L., Carrabba, G. G., Giussani, C. G., Lucini, V., Cerutti, F., Scaglione, F., Landré, J., Pluderi, M., Tomei, G., Villani, R. M., et al. (2001) · PubMed · Cited by 180
Angiogenesis modulation in cancer research: novel clinical approaches
Cristofanilli, M., Charnsangavej, C., & Hortobagyi, G. N. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd819 · Cited by 179
Thrombospondins and tumor angiogenesis
de Fraipont, F., Nicholson, A. C., Feige, J.-J., & Van Meir, E. G. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02102-5 · Cited by 178
Kerbel, R. S., Klement, G., Pritchard, K. I., & Kamen, B. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf093 · Cited by 177
Self-citationTreatment of Children and Young Adults with Early-Stage Non-Hodgkin's Lymphoma
Link, M. P., Shuster, J. J., Donaldson, S. S., Berard, C. W., & Murphy, S. B. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710303371802 · Cited by 172
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
Glode, L. M., Barqawi, A., Crighton, F., Crawford, E. D., & Kerbel, R. (2003) · Cancer · doi:10.1002/cncr.11713 · Cited by 162
Self-citationMulticenter trial of low‐dose paclitaxel in patients with advanced AIDS‐related Kaposi sarcoma
Tulpule, A., Groopman, J., Saville, M. W., Harrington, W., Friedman‐Kien, A., Espina, B. M., Garces, C., Mantelle, L., Mettinger, K., Scadden, D. T., et al. (2002) · Cancer · doi:10.1002/cncr.10634 · Cited by 159
Malingré, M. M., Beijnen, J. H., & Schellens, J. H. M. (2001) · Investigational New Drugs · doi:10.1023/a:1010635000879 · Cited by 158
Why we're losing the war on cancer (and how to win it).
Leaf, C. (2004) · PubMed · Cited by 156
Takahashi, N., Haba, A., Matsuno, F., & Seon, B. K. (2001) · PubMed · Cited by 150
Phase II Study of Temozolomide Plus Thalidomide for the Treatment of Metastatic Melanoma
Hwu, W., Krown, S. E., Menell, J. H., Panageas, K. S., Merrell, J., Lamb, L. A., Williams, L. J., Quinn, C. J., Foster, T., Chapman, P. B., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.061 · Cited by 140
Hahnfeldt, P., Folkman, J., & Hlatky, L. (2003) · Journal of Theoretical Biology · doi:10.1006/jtbi.2003.3162 · Cited by 138
Emmenegger, U., Man, S., Shaked, Y., Francia, G., Wong, J. W., Hicklin, D. J., & Kerbel, R. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0580 · Cited by 133
Self-citationHermans, I. F., Chong, T. W., Palmowski, M. J., Harris, A. L., & Cerundolo, V. (2003) · PubMed · Cited by 128
Stoll, B. R., Migliorini, C., Kadambi, A., Munn, L. L., & Jain, R. K. (2003) · Blood · doi:10.1182/blood-2003-02-0365 · Cited by 120
Yonekura, K., Basaki, Y., Chikahisa, L., et al. (1999) · PubMed · Cited by 116
Gately, S. T., & Kerbel, R. S. (2003) · KARGER eBooks · doi:10.1159/000071373 · Cited by 116
Self-citationThe oral fluoropyrimidines in cancer chemotherapy.
Lamont, E. B., & Schilsky, R. L. (1999) · PubMed · Cited by 113
Childhood acute lymphoblastic leukemia
Pui, C., Relling, M. V., Campana, D., & Evans, W. E. (2002) · Reviews in Clinical and Experimental Hematology · doi:10.1046/j.1468-0734.2002.00067.x · Cited by 108
Danson, S. J., Lorigan, P. C., Arance, A. M., Clamp, A. R., Ranson, M., Hodgetts, J., Lomax, L., Ashcroft, L., Thatcher, N., & Middleton, M. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.039 · Cited by 106
High-Time Chemotherapy or High Time for Low Dose
Kamen, B. A., Rubin, E., Aisner, J., & GLATSTEIN, E. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2935 · Cited by 104
Self-citationVascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis
Huang, J., Soffer, S. Z., Kim, E. S., McCrudden, K. W., Huang, J. T., New, T. N., Manley, C. A., Middlesworth, W., O’Toole, K., Yamashiro, D. J., et al. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.36.2.1 · Cited by 101
Inhibition of angiogenesis by non-toxic doses of temozolomide
Kurzen, H., Schmitt, S., Näher, H., & Möhler, T. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200308000-00003 · Cited by 97
Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism
Eisenhauer, E. A. (1998) · Annals of Oncology · doi:10.1023/a:1008497110734 · Cited by 95
Topical application of methotrexate for inhibition of corneal angiogenesis
Joussen, A. M., Kruse, F. E., Völcker, H. E., & Kirchhof, B. (1999) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s004170050387 · Cited by 90
Zhang, L., Yu, D., Hicklin, D. J., Hannay, J. A. F., Ellis, L. M., & Pollock, R. E. (2002) · PubMed · Cited by 90
Rabascio, C., Muratori, E., Mancuso, P., Calleri, A., Raia, V., Foutz, T. J., Cinieri, S., Veronesi, G., Pruneri, G., Lampertico, P., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0265 · Cited by 85
Sikder, H. A., Huso, D. L., Zhang, H., Wang, B., Ryu, B., Hwang, S. T., Powell, J. D., & Alani, R. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00245-9 · Cited by 78
Taxane-Mediated Antiangiogenesis in Vitro
Ng, S. S. W., Figg, W. D., & Sparreboom, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3391 · Cited by 72
Role of endothelial cell survival and death signals in angiogenesis
Nor, J. E., & Polverini, P. J. (1999) · Angiogenesis · doi:10.1023/a:1009053411094 · Cited by 70
Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms tumor
Soffer, S. Z., Moore, J. T., Kim, E. S., Huang, J., Yokoi, A., Manley, C. A., O’Toole, K., Stolar, C. J. H., Middlesworth, W., Yamashiro, D. J., et al. (2001) · Journal of Pediatric Surgery · doi:10.1053/jpsu.2001.25747 · Cited by 68
Inaba, M., Kobayashi, T., Tashiro, T., Sakurai, Y., Maruo, K., Ohnishi, Y., Ueyama, Y., & Nomura, T. (1989) · Cancer · Cited by 60
Spieth, K., Kaufmann, R., & Gille, J. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0678-9 · Cited by 55
Castilla, M. Á., Caramelo, C. A., Gazapo, R., Martín‐Belloso, O., González‐Pacheco, F. R., Tejedor, A., Bragado, R., & Arroyo, M. V. A. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00693-7 · Cited by 52
Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.
Petrangolini, G., Pratesi, G., Cesare, M. D., Supino, R., Pisano, C., Marcellini, M., Giordano, V., Laccabue, D., Lanzi, C., & Zunino, F. (2003) · PubMed · Cited by 42
Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor
Soffer, S. Z., Kim, E. S., Moore, J. T., Huang, J., Yokoi, A., Manley, C. A., O’Toole, K., Middlesworth, W., Stolar, C. J. H., Yamashiro, D. J., et al. (2001) · Journal of Pediatric Surgery · doi:10.1053/jpsu.2001.28823 · Cited by 36
Bergers, G., & Hanahan, D. (2002) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2002.67.293 · Cited by 29
ABRAHAM, D., ABRI, S., Hofmann, M., HÖLTL, W., & Aharinejad, S. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000075917.98929.57 · Cited by 28
Niitsu, N., & Umeda, M. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199706000-00022 · Cited by 27
CHS 828 Inhibits Neuroblastoma Growth in Mice Alone and in Combination with Antiangiogenic Drugs
Svensson, Å., Bäckman, U., Jonsson, E., Larsson, R. L., & Christofferson, R. H. B. (2002) · Pediatric Research · doi:10.1203/00006450-200205000-00011 · Cited by 25
Anti-angiogenic Chemotherapy in Central Nervous System Tumors
Kieran, M. W. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_19 · Cited by 23
Dunussi‐Joannopoulos, K. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819021000032926 · Cited by 7
Cited by
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653
Self-citationCombination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Metadata
- Authors
- Kerbel, R. S., & Kamen, B. A.
- Venue
- Nature Reviews Cancer
- Published
- 2004-06-01
- Volume
- 4
- Issue
- 6
- Pages
- 423-436
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2169965478
- Cited by
- 1,397
- References
- 108
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.